These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3573681)

  • 1. [Effect of an allopurinol/benzbromaron preparation on the composition of urine in a circadian course].
    Hesse A; Schneeberger W; Vahlensieck W
    Klin Wochenschr; 1987 Mar; 65(5):218-24. PubMed ID: 3573681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prevention of urinary calculi by means of a benzbromarone-citrate combination].
    Bach D; Hesse A; Strenge A; Vahlensieck W
    Fortschr Med; 1980 Nov; 98(44):1752-5. PubMed ID: 7461567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of hyperuricaemia with a combination of allopurinol and benzbromaron (author's transl)].
    Matzkies F; Berg G
    Dtsch Med Wochenschr; 1976 Oct; 101(43):1568-70. PubMed ID: 991731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of uric acid lowering drugs in low dosage in patients with hyperuricemia and hypertriglyceridemia in a randomized group study].
    Arntz HR; Dreykluft HR; Leonhardt H
    Fortschr Med; 1979 Jul; 97(27):1212-4. PubMed ID: 457017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol?
    Mertz DP; Eichhorn R
    Klin Wochenschr; 1984 Dec; 62(24):1170-2. PubMed ID: 6530890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urine composition in patients with renal stone disease during treatment with allopurinol.
    Tiselius HG; Larsson L
    Scand J Urol Nephrol; 1980; 14(1):65-71. PubMed ID: 7375845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapy with alllopurinol and benzbromarone, single and combined. Renal elimination of lithogenous and colloid protective substances (author's transl)].
    Mertz DP
    Med Klin; 1977 Apr; 72(15):664-8. PubMed ID: 857138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benzbromarone therapy in hyperuricaemia; comparison with allopurinol and probenecid.
    Schepers GW
    J Int Med Res; 1981; 9(6):511-5. PubMed ID: 7033016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Uric acid lowering effects of benzbromarone (Harolan) by increasing uric acid excretion].
    Fortschr Med; 1979 May; 97(17):835-6. PubMed ID: 437646
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of oral purine load and allopurinol on the crystallization of calcium salts in urine of patients with hyperuricosuric calcium urolithiasis.
    Pak CY; Barilla DE; Holt K; Brinkley L; Tolentino R; Zerwekh JE
    Am J Med; 1978 Oct; 65(4):593-9. PubMed ID: 707519
    [No Abstract]   [Full Text] [Related]  

  • 11. The excretion of glycosaminoglycans in the urine of calcium-oxalate-stone patients and healthy persons.
    Hesse A; Wuzel H; Vahlensieck W
    Urol Int; 1986; 41(2):81-7. PubMed ID: 3727195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Uric acid-lowering effect of a combination of benzbromarone and allopurinol--studies under standardized dietary conditions].
    Löffler W; Gröbner W; Zöllner N
    Arzneimittelforschung; 1983; 33(12):1687-91. PubMed ID: 6686776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The uric acid-lowering action of benzbromarone effervescent granules and allopurinol. Comparative studies (author's transl)].
    Mertz DP
    MMW Munch Med Wochenschr; 1978 Oct; 120(42):1387-90. PubMed ID: 101792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The correction of hyperuricemia in patients with different forms of nephrolithiasis using allopurinol and Allomaron].
    Darenkov AF; Konstantinova OV; Ianenko EK
    Urol Nefrol (Mosk); 1994; (5):35-7. PubMed ID: 7871619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
    Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
    Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Change in inhibitory potential in urine of hyperuricosuric calcium oxalate stone formers effected by allopurinol and orthophosphates.
    Goldwasser B; Sarig S; Azoury R; Wax Y; Hirsch D; Perlberg S; Many M
    J Urol; 1984 Nov; 132(5):1008-11. PubMed ID: 6492268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of calcium oxalate crystal growth in urine during treatment with allopurinol.
    Tiselius HG
    Br J Urol; 1980 Jun; 52(3):189-92. PubMed ID: 7426978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Serum uric acid and uric acid elimination after benzbromarone therapy in patients with gout and hyperuricemia].
    Matzkies F; Neuwirth R; Berg G
    Fortschr Med; 1976 Sep; 94(26):1427-9. PubMed ID: 976920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of allopurinol treatment on stone formation on hyperuricosuric calcium oxalate stone-formers.
    Favus MJ; Coe FL
    Scand J Urol Nephrol Suppl; 1980; 53():265-71. PubMed ID: 6938003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of oxalate and calcium oxalate activity and formation product ratio in patients with renal stones before and during treatment.
    Peña JC; Monforte MF; Briceño A
    J Urol; 1987 Nov; 138(5):1137-40. PubMed ID: 3669156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.